Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30879097 | 0.86 | FAAH (0.41) | FAAHELANEUSP30BCHEPOLB | |
| SCHEMBL16059069 | 0.84 | FAAH (0.40) | FAAHELANEUSP30BCHEPOLB | |
| SCHEMBL22501848 | 0.79 | ELANE (0.44) | FAAHELANEUSP30BCHEPOLB | |
| SCHEMBL693588 | 0.77 | FAAH (0.41) | FAAHELANEUSP30BCHEPOLB | |
| SCHEMBL22951279 | 0.76 | FAAH (0.40) | FAAHELANEUSP30BCHEPOLB | |
| SCHEMBL1864917 | 0.76 | FAAH (0.40) | FAAHELANEUSP30BCHEPOLB | |
| SCHEMBL22233152 | 0.74 | FAAH (0.39) | FAAHELANEUSP30BCHEPOLB | |
| SCHEMBL28739878 | 0.74 | ELANE (0.42) | FAAHELANEUSP30BCHEPOLB | |
| SCHEMBL12516112 | 0.74 | FAAH (0.39) | FAAHELANEBCHE | |
| SCHEMBL23627885 | 0.74 | NR1H2 (0.39) | FAAHUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2025-09-23 | — | — | US | disclosed |
| WO-2025087365-A1 | METTL3 INHIBITOR | 杭州邦顺制药有限公司 | 2025-05-01 | — | — | WO | disclosed |
| CN-119899188-A | METTL3 inhibitors | 杭州邦顺制药有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-20250129077-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2025-04-24 | — | — | US | disclosed |
| EP-4139295-B1 | ISOQUINILINE NRF2 AGONISTS | C4X DISCOVERY LTD (GB) | 2025-04-09 | — | — | EP | disclosed |
| CN-115667242-B | Tetrahydroisoquinoline compounds as NRF2 activators | 希四克斯探索有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4512816-A2 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-112533607-B | TLR7 agonists | 普利缪尼治疗学股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-3801538-B1 | TLR7 AGONISTS | PRIMMUNE THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-12037335-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-8674088-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586744-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2422791-A1 | Antiviral phosphinate compounds | Gilead Sciences, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7893264-B2 | viricides comprising phosphinic acid compounds and/or mixed with carriers, nucleoside analogues, interferons or pegylated interferons; treating hepatitis C or a hepatitis C associated disorders in animals; side effect reduction | GILEAD SCIENCES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| EP-2043658-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080057031-A1 | Antiviral phosphinate compounds | PHOSPHO1, MAVS, ITPA | FAAH 4108/4885ELANE 2970/4885USP30 1489/4885 |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | FAAH 4108/4885ELANE 2970/4885USP30 1489/4885 |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | FAAH 282/4885ELANE 279/4885USP30 2723/4885 |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | FAAH 4108/4885ELANE 2970/4885USP30 1489/4885 |
| US-12037335-B2 | Substituted purines as TLR7 agonists | TLR7, TLR9, TLR1 | FAAH 1634/4885ELANE 2928/4885USP30 3489/4885 |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | HAVCR2, PHOSPHO1, EIF2AK2 | FAAH 3150/4885ELANE 1326/4885USP30 1663/4885 |
| US-20250129077-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | TLR7, TLR9, TLR1 | FAAH 1634/4885ELANE 2928/4885USP30 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.